Vertex Pain Drug Fails to Outperform Placebo in Key Study, Raising Concerns

Vertex Pharmaceuticals' suzetrigine showed pain reduction but did not surpass placebo results in a Phase 2 trial, leading to a sharp drop in its stock value.

• Vertex's non-opioid pain drug suzetrigine reduced pain compared to baseline but failed to outperform a placebo in a Phase 2 trial for lumbosacral radiculopathy (LSR).
• The trial results led to Vertex's stock plunging by up to 16%, its largest intraday drop in four years, erasing its year-to-date gains.
• The company attributed the mixed results to variability in placebo responses and plans to address this in a late-stage Phase 3 trial.
• Suzetrigine, a potential new class of non-addictive pain medication, has been viewed as a key part of Vertex's strategy to diversify beyond cystic fibrosis treatments.
• Some analysts questioned the drug's commercial viability, citing competition from cheaper opioids and skepticism about its future success in chronic pain treatment.

3 Articles

Investopedia Boston Globe Stat News